Cutera Announces Fourth Quarter and Full-Year 2023 Financial Results Along with 2024 Outlook
- Revenue for Q4 2023 was $49.5 million, full-year 2023 revenue reached $212.4 million
- Cash and marketable securities were $143.6 million as of December 31, 2023
- Successful completion of corporate restructuring program for improved cost structure and organizational alignment
- North American commercial release of enhanced AviClear product during Q4 2023
- Gross profit for Q4 2023 was $6.2 million, non-GAAP gross profit was $9.9 million
- Operating expenses for Q4 2023 were $50.6 million
- Revenue related to capital equipment systems declined 32% in Q4 2023
- Full-year 2023 revenue decreased by 16% compared to 2022
- 2024 outlook projects annual revenue in the range of $160 million to $170 million
- Conference call scheduled to discuss financial results and related matters
- Revenue declines in Q4 and full-year 2023 compared to previous periods
- Gross profit decrease in Q4 2023 compared to Q4 2022
- Non-GAAP operating income loss in Q4 2023
- Cash and marketable securities decreased from 2022 to 2023
- Operating expenses increased in full-year 2023 compared to the prior year
Insights
The reported financial results for Cutera, Inc. reflect a significant revenue decline of 26% for the fourth quarter and 16% for the full year compared to the previous year. This downturn is primarily attributed to a decrease in capital equipment systems sales, which plummeted by 32% and a lesser yet notable decline in recurring revenue streams, which fell by 16%. These figures are concerning as they may indicate a shrinking demand for Cutera's products or potential saturation in the aesthetic and dermatology market segments.
The company's gross profit margins have also taken a substantial hit, dropping from over 55% to approximately 28% for the full year. This reduction in profitability could be due to several factors such as increased production costs, pricing pressures, or inventory write-downs. The latter is evidenced by the reported non-cash expense related to excess and obsolete inventory, which negatively impacted gross profit by approximately $8.4 million, or 16.9% of revenue, for the fourth quarter.
Investors should note the company's operational restructuring, which, while potentially beneficial in the long run, has likely contributed to short-term financial stress. The restructuring includes a reduction in workforce, bringing manufacturing operations in-house and transitioning the Skincare business. These changes could result in cost savings and improved operational efficiency in future periods.
From a financial perspective, Cutera's cash and marketable securities position decreased notably from $317.3 million at the end of 2022 to $143.6 million at the end of 2023. This reduction in liquidity could raise concerns about the company's cash burn rate and its ability to sustain operations without additional financing, especially in light of the projected revenue decline for 2024.
The company forecasts a further decrease in annual revenue for 2024, with expectations ranging from $160 million to $170 million. This outlook suggests that management anticipates continued challenges in the market or within the company's operational framework. The projected ending cash and marketable securities for 2024 between $55 million to $60 million may also indicate significant cash usage, which could be a red flag for investors regarding the company's financial stability.
Despite these challenges, the limited commercial release of the enhanced AviClear product could represent a potential growth opportunity. However, with only $3.9 million in revenue for the fourth quarter, it remains to be seen whether this product can significantly contribute to a turnaround in the company's financial performance.
The financial results for Cutera, Inc. suggest potential strategic misalignments or market pressures within the medical aesthetics industry. The substantial decline in capital equipment sales could be indicative of increased competition or a shift in consumer preferences towards non-invasive procedures that do not require costly equipment. Additionally, the decline in recurring revenue streams might hint at a saturation of after-sales service contracts or consumables, which are typically stable revenue sources for medical device companies.
The restructuring efforts, including the in-house transition of critical manufacturing operations, may be an attempt to regain control over production costs and improve profit margins. However, such transitions can be complex and may not yield immediate financial benefits. The decrease in gross profit margin is particularly stark and suggests that the company's cost of goods sold has risen or that it has had to offer substantial discounts to maintain sales volumes.
With the medical device industry being highly regulated and competitive, Cutera's ability to navigate these challenges while investing in innovation, such as the AviClear product, will be important to its long-term success. Stakeholders should closely monitor the company's strategic initiatives and market response to new product offerings.
-
Consolidated revenue for the fourth quarter of 2023 of
$49.5 million -
Full-year 2023 revenue of
$212.4 million $205 million -
Cash and marketable securities of
$143.6 million $135 million - Completion of corporate restructuring program, allowing for both an improved cost structure and better organizational alignment
- Successful execution of the North American limited commercial release of the enhanced AviClear product and business model offering during the fourth quarter of 2023
“Thanks to the hard work of the team, Cutera finished a challenging year with fourth quarter financial performance ahead of our guidance range, and we have also completed the key elements of our corporate restructuring, including a reduction in force, bringing critical manufacturing operations in-house, and a transition of our Skincare business,” commented Taylor Harris, Chief Executive Officer of Cutera, Inc. “We are now squarely focused on our most important priorities, which are operational excellence and building a successful AviClear franchise across the globe.”
Fourth Quarter 2023 Financial Highlights
Consolidated revenue for the fourth quarter of 2023 was
Gross profit was
Operating expenses were
Non-GAAP operating income was a loss of
Cash and marketable securities were
Full-Year 2023 Financial Highlights
Consolidated revenue for the full-year 2023 was
Gross profit was
Operating expenses were
Non-GAAP operating income was a loss of
2024 Outlook
The Company expects 2024 annual revenue in the range of
Conference Call
The Company’s management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating in the call will be Taylor Harris, Chief Executive Officer, Stuart Drummond, Interim Chief Financial Officer, and Greg Barker, Vice President of FP&A and Investor Relations.
Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open until the end of the live conference call.
If participants prefer to dial in and speak with an operator, dial
The call will also be webcast and can be accessed from the Investor Relations section of Cutera’s website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
About Cutera, Inc.
*Use of Non-GAAP Financial Measures
In this press release, to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for gross margin, gross margin rate, and operating income. Non-GAAP adjustments include depreciation and amortization including contract acquisition costs, stock-based compensation, enterprise resource planning (“ERP”) implementation costs, certain legal and litigation costs, executive and other non-recurring severance costs, retention plan costs, expenses related to manufacturing agreement termination, and Board of Director legal and advisory fees. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.
The Company defines non-GAAP financial measure, also commonly known as adjusted EBITDA, as operating income before depreciation and amortization, stock-based compensation, ERP implementation costs, costs related to certain litigation, executive and non-recurring severance costs, retention plan costs, expenses related to manufacturing agreement termination, and legal and advisory fees related to litigation and shareholder activism.
Company management uses non-GAAP measures as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:
Depreciation and amortization, including contract acquisition costs. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;
Stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;
ERP implementation costs. The Company has excluded ERP system costs related to direct and incremental costs incurred in connection with its multi-phase implementation of a new ERP solution and the related technology infrastructure costs. The Company excludes these costs because it believes that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of the Company’s operating performance;
Certain legal and litigation costs. The Company has excluded costs incurred related to its litigation against Lutronic Aesthetics, which is not part of the Company’s ordinary course of business. The Company’s complaint against Lutronic alleges misappropriation of trade secrets, violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), interference with contractual relations and other claims. The Company excludes these costs because this litigation is a result of a discrete event that was not part of the Company’s business strategy, but has a significant effect on the results of operations. Its costs are incidental to and do not reflect the efficiencies and effectiveness of the Company’s core operations;
Executive and other non-recurring severance costs. The Company has excluded costs associated with restructuring activities and the separation of its officers and other executives in calculating its non-GAAP operating expenses and non-GAAP Operating Income. The Company has excluded restructuring costs because a restructuring represents a discrete event that signifies a change in the Company’s strategy, but its costs are not indicative of the ongoing financial performance of the business. The Company excludes executive separation costs because executive separations are unpredictable and not part of the Company’s business strategy but could have a significant impact on the results of operation;
Retention plan costs. The Company has excluded the expense related to a retention plan implemented in April 2023. Approximately
Expenses related to manufacturing agreement termination. The Company has excluded expenses related to a manufacturing agreement termination incurred as part of a settlement agreement related to the non-renewal of a manufacturing service agreement with Jabil Inc., a third-party manufacturing provider that manufactured excel V+ and AviClear devices for the Company. The Company excluded these costs because it believes that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of the Company’s operating performance; and
Board of Director legal and advisory fees. The Company has excluded costs associated with the litigation and shareholder activism related to its 2023 annual meeting of shareholders. The Company excluded these costs as the costs do not relate to ongoing operations.
The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations.
Safe Harbor Statement
Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include but are not limited to, Cutera’s plans, objectives, strategies, financial performance, guidance and outlook, product launches and performance, trends, prospects, or future events and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.
All statements made in this release are made only as of the date set forth at the beginning of this release. We undertake no obligation to update the information made in this release in the event facts or circumstances subsequently change after the date of this release. Our audited consolidated financial statements for the year ended December 31, 2023 are not yet available. As a result, all financial results described in this earnings release should be considered preliminary, and are subject to change to reflect any necessary adjustments or changes in accounting estimates, that are identified prior to the time we file our Form 10-K.
| CUTERA, INC. | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (in thousands) | |||||||
| (unaudited) | |||||||
December 31, |
December 31, |
||||||
2023 |
2022 |
||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ |
143,612 |
|
$ |
145,924 |
|
|
| Marketable securities |
|
- |
|
|
171,390 |
|
|
| Accounts receivable, net |
|
43,371 |
|
|
45,562 |
|
|
| Inventories, net |
|
61,725 |
|
|
63,628 |
|
|
| Other current assets and prepaid expenses |
|
19,627 |
|
|
24,036 |
|
|
| Restricted cash |
|
- |
|
|
700 |
|
|
| Total current assets |
|
268,335 |
|
|
451,240 |
|
|
| Long-term inventories, net |
|
26,011 |
|
|
- |
|
|
| Property and equipment, net |
|
37,275 |
|
|
40,368 |
|
|
| Deferred tax asset |
|
579 |
|
|
590 |
|
|
| Goodwill |
|
1,339 |
|
|
1,339 |
|
|
| Operating lease right-of-use assets |
|
10,055 |
|
|
12,831 |
|
|
| Other long-term assets |
|
11,575 |
|
|
14,620 |
|
|
| Total assets | $ |
355,169 |
|
$ |
520,988 |
|
|
| Liabilities and Stockholders' Deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ |
19,829 |
|
$ |
33,736 |
|
|
| Accrued liabilities |
|
51,930 |
|
|
57,452 |
|
|
| Operating leases liabilities |
|
2,441 |
|
|
2,810 |
|
|
| Deferred revenue |
|
10,422 |
|
|
11,841 |
|
|
| Total current liabilities |
|
84,622 |
|
|
105,839 |
|
|
| Deferred revenue, net of current portion |
|
1,494 |
|
|
1,657 |
|
|
| Operating lease liabilities, net of current portion |
|
8,887 |
|
|
11,352 |
|
|
| Convertible notes, net of unamortized debt issuance costs |
|
418,695 |
|
|
416,459 |
|
|
| Other long-term liabilities |
|
1,298 |
|
|
862 |
|
|
| Total liabilities |
|
514,996 |
|
|
536,169 |
|
|
| Stockholders’ deficit: | |||||||
| Common stock |
|
20 |
|
|
20 |
|
|
| Additional paid-in capital |
|
131,496 |
|
|
125,406 |
|
|
| Accumulated other comprehensive loss |
|
- |
|
|
(94 |
) |
|
| Accumulated deficit |
|
(291,343 |
) |
|
(140,513 |
) |
|
| Total stockholders' deficit |
|
(159,827 |
) |
|
(15,181 |
) |
|
| Total liabilities and stockholders' deficit | $ |
355,169 |
|
$ |
520,988 |
|
|
| CUTERA, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (in thousands, except per share data) | |||||||||||||||
| (unaudited) | |||||||||||||||
Three Months Ended |
Twelve Months Ended |
||||||||||||||
December 31, |
December 31, |
December 31, |
December 31, |
||||||||||||
2023 |
2022 |
2023 |
2022 |
||||||||||||
| Products | $ |
43,528 |
|
$ |
61,601 |
|
$ |
189,813 |
|
$ |
228,796 |
|
|||
| Service |
|
6,012 |
|
|
5,752 |
|
|
22,556 |
|
|
23,603 |
|
|||
| Total net revenue |
|
49,540 |
|
|
67,353 |
|
|
212,369 |
|
|
252,399 |
|
|||
| Products |
|
40,684 |
|
|
26,188 |
|
|
139,380 |
|
|
100,254 |
|
|||
| Service |
|
2,615 |
|
|
2,416 |
|
|
12,576 |
|
|
12,316 |
|
|||
| Total cost of revenue |
|
43,299 |
|
|
28,604 |
|
|
151,956 |
|
|
112,570 |
|
|||
| Gross margin |
|
6,241 |
|
|
38,749 |
|
|
60,413 |
|
|
139,829 |
|
|||
| Gross margin % |
|
12.6 |
% |
|
57.5 |
% |
|
28.4 |
% |
|
55.4 |
% |
|||
| Operating expenses: | |||||||||||||||
| Sales and marketing |
|
24,412 |
|
|
28,514 |
|
|
113,003 |
|
|
106,947 |
|
|||
| Research and development |
|
4,564 |
|
|
5,408 |
|
|
21,408 |
|
|
25,155 |
|
|||
| General and administrative |
|
21,581 |
|
|
10,363 |
|
|
69,029 |
|
|
45,917 |
|
|||
| Total operating expenses |
|
50,557 |
|
|
44,285 |
|
|
203,440 |
|
|
178,019 |
|
|||
| Loss from operations |
|
(44,316 |
) |
|
(5,536 |
) |
|
(143,027 |
) |
|
(38,190 |
) |
|||
| Interest and other income (expense), net | |||||||||||||||
Interest on convertible notes |
|
(2,944 |
) |
|
(1,992 |
) |
|
(11,780 |
) |
|
(5,658 |
) |
|||
Loss on extinguishment of convertible notes |
|
- |
|
|
- |
|
|
- |
|
|
(34,423 |
) |
|||
Amortization of debt issuance costs |
|
(566 |
) |
|
(438 |
) |
|
(2,236 |
) |
|
(1,355 |
) |
|||
Interest income, net |
|
1,761 |
|
|
1,535 |
|
|
8,707 |
|
|
2,914 |
|
|||
Other income (expense), net |
|
1,604 |
|
|
(593 |
) |
|
(960 |
) |
|
(3,990 |
) |
|||
| Loss before income taxes |
|
(44,461 |
) |
|
(7,024 |
) |
|
(149,296 |
) |
|
(80,702 |
) |
|||
| Income tax expense |
|
769 |
|
|
764 |
|
|
1,534 |
|
|
1,638 |
|
|||
| Net loss | $ |
(45,230 |
) |
$ |
(7,788 |
) |
$ |
(150,830 |
) |
$ |
(82,340 |
) |
|||
| Net loss per share: | |||||||||||||||
| Basic | $ |
(2.27 |
) |
$ |
(0.40 |
) |
$ |
(7.59 |
) |
$ |
(4.39 |
) |
|||
| Diluted | $ |
(2.27 |
) |
$ |
(0.40 |
) |
$ |
(7.59 |
) |
$ |
(4.39 |
) |
|||
| Weighted-average number of shares used in per share calculations: | |||||||||||||||
| Basic |
|
19,958 |
|
|
19,642 |
|
|
19,885 |
|
|
18,747 |
|
|||
| Diluted |
|
19,958 |
|
|
19,642 |
|
|
19,885 |
|
|
18,747 |
||||
| CUTERA, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
Three Months Ended |
Twelve Months Ended |
||||||||||||||
December 31, |
December 31, |
December 31, |
December 31, |
||||||||||||
2023 |
2022 |
2023 |
2022 |
||||||||||||
| Cash flows from operating activities: | |||||||||||||||
| Net loss | $ |
(45,230 |
) |
$ |
(7,788 |
) |
$ |
(150,830 |
) |
$ |
(82,340 |
) |
|||
| Adjustments to reconcile net loss to net cash provided used in operating activities: | |||||||||||||||
| Stock-based compensation |
|
1,512 |
|
|
1,379 |
|
|
8,064 |
|
|
14,400 |
|
|||
| Depreciation and amortization |
|
3,350 |
|
|
1,018 |
|
|
8,575 |
|
|
2,621 |
|
|||
| Amortization of contract acquisition costs |
|
1,762 |
|
|
1,385 |
|
|
8,847 |
|
|
3,200 |
|
|||
| Amortization of debt issuance costs |
|
566 |
|
|
438 |
|
|
2,236 |
|
|
1,355 |
|
|||
| Deferred tax assets |
|
(51 |
) |
|
36 |
|
|
11 |
|
|
188 |
|
|||
| Provision for credit losses |
|
1,893 |
|
|
1,110 |
|
|
7,381 |
|
|
1,787 |
|
|||
| Loss on sale of property and equipment |
|
- |
|
|
82 |
|
|
- |
|
|
168 |
|
|||
| Accretion of discount on investment securities and investment income, net |
|
- |
|
|
- |
|
|
1,048 |
|
|
- |
|
|||
| Loss on extinguishment of convertible notes |
|
- |
|
|
- |
|
|
- |
|
|
34,423 |
|
|||
| Changes in assets and liabilities: | |||||||||||||||
| Accounts receivable |
|
4,565 |
|
|
(10,796 |
) |
|
(5,190 |
) |
|
(15,900 |
) |
|||
| Inventories, net |
|
5,171 |
|
|
(7,690 |
) |
|
6,952 |
|
|
(36,305 |
) |
|||
| Other current assets and prepaid expenses |
|
10 |
|
|
(364 |
) |
|
4,362 |
|
|
(9,491 |
) |
|||
| Other long-term assets |
|
(601 |
) |
|
(4,447 |
) |
|
(6,243 |
) |
|
(8,091 |
) |
|||
| Accounts payable |
|
(10,131 |
) |
|
537 |
|
|
(14,866 |
) |
|
20,979 |
|
|||
| Accrued liabilities |
|
4,617 |
|
|
6,966 |
|
|
(6,346 |
) |
|
3,282 |
|
|||
| Operating leases, net |
|
(14 |
) |
|
10 |
|
|
(58 |
) |
|
56 |
|
|||
| Deferred revenue |
|
(1,192 |
) |
|
1,097 |
|
|
(1,582 |
) |
|
2,673 |
|
|||
| Net cash used in operating activities |
|
(33,773 |
) |
|
(17,027 |
) |
|
(137,639 |
) |
|
(66,995 |
) |
|||
| Cash flows from investing activities: | |||||||||||||||
| Acquisition of property and equipment |
|
(2,599 |
) |
|
(8,591 |
) |
|
(33,241 |
) |
|
(22,698 |
) |
|||
| Purchase of marketable investments |
|
- |
|
|
(77,202 |
) |
|
(23,467 |
) |
|
(233,511 |
) |
|||
| Proceeds from maturities of marketable investments |
|
- |
|
|
111,000 |
|
|
193,903 |
|
|
62,027 |
|
|||
| Net cash provided by (used in) investing activities |
|
(2,599 |
) |
|
25,207 |
|
|
137,195 |
|
|
(194,182 |
) |
|||
| Cash flows from financing activities: | |||||||||||||||
| Proceeds from exercise of stock options and employee stock purchase plan |
|
- |
|
|
1,036 |
|
|
1,323 |
|
|
2,723 |
|
|||
| Proceeds from issuance of convertible notes |
|
- |
|
|
120,000 |
|
|
- |
|
|
360,000 |
|
|||
| Purchase of capped call |
|
- |
|
|
- |
|
|
- |
|
|
(31,671 |
) |
|||
| Payment of issuance costs of capped call |
|
- |
|
|
(25,009 |
) |
|
- |
|
|
(25,362 |
) |
|||
| Payment of issuance costs of convertible notes |
|
- |
|
|
(3,600 |
) |
|
- |
|
|
(11,202 |
) |
|||
| Extinguishment of convertible notes |
|
- |
|
|
- |
|
|
- |
|
|
(45,777 |
) |
|||
| Taxes paid related to net share settlement of equity awards |
|
(24 |
) |
|
(436 |
) |
|
(3,297 |
) |
|
(5,256 |
) |
|||
| Payments on capital lease obligations |
|
(208 |
) |
|
(127 |
) |
|
(594 |
) |
|
(518 |
) |
|||
| Net cash provided by (used in) financing activities |
|
(232 |
) |
|
91,864 |
|
|
(2,568 |
) |
|
242,937 |
|
|||
| Net increase (decrease) in cash, cash equivalents and restricted cash |
|
(36,604 |
) |
|
100,044 |
|
|
(3,012 |
) |
|
(18,240 |
) |
|||
| Cash, cash equivalents, and restricted cash at beginning of period |
|
180,216 |
|
|
46,580 |
|
|
146,624 |
|
|
164,864 |
|
|||
| Cash, cash equivalents, and restricted cash at end of period | $ |
143,612 |
|
$ |
146,624 |
|
$ |
143,612 |
|
$ |
146,624 |
|
|||
| CUTERA, INC. | |||||||||||||||||||||
| CONSOLIDATED FINANCIAL HIGHLIGHTS | |||||||||||||||||||||
| (in thousands, except percentage data) | |||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||
Three Months Ended |
% Change |
Twelve Months Ended |
% Change |
||||||||||||||||||
December 31, |
December 31, |
2023 Vs |
December 31, |
December 31, |
2023 Vs |
||||||||||||||||
2023 |
2022 |
2022 |
2023 |
2022 |
2022 |
||||||||||||||||
| Revenue By Geography: | |||||||||||||||||||||
$ |
22,292 |
|
$ |
34,076 |
|
-34.6 |
% |
$ |
106,786 |
|
$ |
128,426 |
|
-16.9 |
% |
||||||
|
14,887 |
|
|
16,980 |
|
-12.3 |
% |
|
52,134 |
|
|
64,920 |
|
-19.7 |
% |
||||||
| Rest of World |
|
12,361 |
|
|
16,297 |
|
-24.2 |
% |
|
53,449 |
|
|
59,053 |
|
-9.5 |
% |
|||||
| Total Net Revenue | $ |
49,540 |
|
$ |
67,353 |
|
-26.4 |
% |
$ |
212,369 |
|
$ |
252,399 |
|
-15.9 |
% |
|||||
International as a percentage of total revenue |
|
55.0 |
% |
|
49.4 |
% |
|
49.7 |
% |
|
49.1 |
% |
|||||||||
| Revenue By Product Category: | |||||||||||||||||||||
| Systems | |||||||||||||||||||||
| - |
$ |
15,456 |
|
$ |
25,684 |
|
-39.8 |
% |
$ |
75,206 |
|
$ |
99,267 |
|
-24.2 |
% |
|||||
| - Rest of World (including |
|
13,668 |
|
|
17,438 |
|
-21.6 |
% |
|
55,322 |
|
|
65,292 |
|
-15.3 |
% |
|||||
| Total Systems |
|
29,124 |
|
|
43,122 |
|
-32.5 |
% |
|
130,528 |
|
|
164,559 |
|
-20.7 |
% |
|||||
| Consumables |
|
5,116 |
|
|
6,702 |
|
-23.7 |
% |
|
25,302 |
|
|
21,737 |
|
+ |
||||||
| Skincare |
|
9,288 |
|
|
11,777 |
|
-21.1 |
% |
|
33,983 |
|
|
42,500 |
|
-20.0 |
% |
|||||
| Total Products |
|
43,528 |
|
|
61,601 |
|
-29.3 |
% |
|
189,813 |
|
|
228,796 |
|
-17.0 |
% |
|||||
| Service |
|
6,012 |
|
|
5,752 |
|
+ |
|
22,556 |
|
|
23,603 |
|
-4.4 |
% |
||||||
| Total Net Revenue | $ |
49,540 |
|
$ |
67,353 |
|
-26.4 |
% |
$ |
212,369 |
|
$ |
252,399 |
|
-15.9 |
% |
|||||
Three Months Ended |
Twelve Months Ended |
||||||||||||||||||||
December 31, |
December 31, |
December 31, |
December 31, |
||||||||||||||||||
2023 |
2022 |
2023 |
2022 |
||||||||||||||||||
| Pre-tax Stock-Based Compensation Expense: | |||||||||||||||||||||
| Cost of revenue | $ |
45 |
|
$ |
235 |
|
$ |
751 |
|
$ |
1,665 |
|
|||||||||
| Sales and marketing |
|
363 |
|
|
1,143 |
|
|
3,388 |
|
|
4,998 |
|
|||||||||
| Research and development |
|
152 |
|
|
(108 |
) |
|
1,082 |
|
|
2,405 |
|
|||||||||
| General and administrative |
|
952 |
|
|
109 |
|
|
2,843 |
|
|
5,332 |
|
|||||||||
$ |
1,512 |
|
$ |
1,379 |
|
$ |
8,064 |
|
$ |
14,400 |
|
||||||||||
| CUTERA, INC. | ||||||||||||||||||||||||||
| RECONCILIATION OF GAAP GROSS PROFIT, GROSS MARGIN AND OPERATING INCOME TO NON-GAAP GROSS PROFIT, GROSS MARGIN AND OPERATING INCOME | ||||||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||
| Three Months Ended December 31, 2023 | Gross Profit |
Gross Margin |
Operating Income |
Twelve Months Ended December 31, 2023 |
Gross Profit |
Gross Margin |
Operating Income |
|||||||||||||||||||
| Reported | $ |
6,241 |
12.6 |
% |
$ |
(44,316 |
) |
Reported | $ |
60,413 |
|
28.4 |
% |
$ |
(143,027 |
) |
||||||||||
| Adjustments: | Adjustments: | |||||||||||||||||||||||||
| Depreciation and amortization including contract acquisition costs |
|
3,237 |
6.5 |
% |
|
5,112 |
|
Depreciation and amortization including contract acquisition costs |
|
9,205 |
|
4.3 |
% |
|
17,422 |
|
||||||||||
| Stock-based compensation |
|
45 |
0.1 |
% |
|
1,512 |
|
Stock-based compensation |
|
751 |
|
0.4 |
% |
|
8,064 |
|
||||||||||
| ERP implementation costs |
|
- |
- |
|
|
780 |
|
ERP implementation costs |
|
- |
|
- |
|
|
3,525 |
|
||||||||||
| Legal |
|
- |
- |
|
|
864 |
|
Legal |
|
- |
|
- |
|
|
2,472 |
|
||||||||||
| Severance |
|
337 |
0.7 |
% |
|
1,132 |
|
Severance |
|
607 |
|
0.3 |
% |
|
2,023 |
|
||||||||||
| Retention plan costs |
|
34 |
0.1 |
% |
|
1,029 |
|
Retention plan costs |
|
129 |
|
0.1 |
% |
|
5,367 |
|
||||||||||
| Expenses related to manufacturing agreement termination |
|
- |
- |
|
|
5,724 |
|
Expenses related to manufacturing agreement termination |
|
- |
|
- |
|
|
5,724 |
|
||||||||||
| Board of Directors legal and advisory fees |
|
- |
- |
|
|
1,827 |
|
Board of Directors legal and advisory fees |
|
- |
|
- |
|
|
11,566 |
|
||||||||||
| Other adjustments |
|
- |
- |
|
|
227 |
|
Other adjustments |
|
307 |
|
0.1 |
% |
|
1,213 |
|
||||||||||
| Total adjustments |
|
3,653 |
7.4 |
% |
|
18,207 |
|
Total adjustments |
|
10,999 |
|
5.2 |
% |
|
57,376 |
|
||||||||||
| Adjusted | $ |
9,894 |
20.0 |
% |
$ |
(26,109 |
) |
Adjusted | $ |
71,412 |
|
33.6 |
% |
$ |
(85,651 |
) |
||||||||||
| Three Months Ended December 31, 2022 | Gross Profit |
Gross Margin |
Operating Income |
Twelve Months Ended December 31, 2022 |
Gross Profit |
Gross Margin |
Operating Income |
|||||||||||||||||||
| Reported | $ |
38,749 |
57.5 |
% |
$ |
(5,536 |
) |
Reported | $ |
139,829 |
|
55.4 |
% |
$ |
(38,190 |
) |
||||||||||
| Adjustments: | Adjustments: | |||||||||||||||||||||||||
| Depreciation and amortization including contract acquisition costs |
|
997 |
1.5 |
% |
|
2,479 |
|
Depreciation and amortization including contract acquisition costs |
|
1,593 |
|
0.6 |
% |
|
5,821 |
|
||||||||||
| Stock-based compensation |
|
235 |
0.3 |
% |
|
1,379 |
|
Stock-based compensation |
|
1,665 |
|
0.7 |
% |
|
14,400 |
|
||||||||||
| ERP implementation costs |
|
- |
- |
|
|
1,498 |
|
ERP implementation costs |
|
- |
|
- |
|
|
9,210 |
|
||||||||||
| Legal |
|
- |
- |
|
|
222 |
|
Legal |
|
- |
|
- |
|
|
1,284 |
|
||||||||||
| Severance |
|
- |
- |
|
|
200 |
|
Severance |
|
26 |
|
0.0 |
% |
|
615 |
|
||||||||||
| Other adjustments |
|
- |
- |
|
|
- |
|
Other adjustments |
|
(290 |
) |
-0.1 |
% |
|
(290 |
) |
||||||||||
| Total adjustments |
|
1,232 |
1.8 |
% |
|
5,778 |
|
Total adjustments |
|
2,994 |
|
1.2 |
% |
|
31,040 |
|
||||||||||
| Adjusted | $ |
39,981 |
59.4 |
% |
$ |
242 |
|
Adjusted | $ |
142,823 |
|
56.6 |
% |
$ |
(7,150 |
) |
||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321616845/en/
Cutera, Inc.
Greg Barker
VP, Corporate FP&A and Investor Relations
415-657-5500
IR@cutera.com
Source: Cutera, Inc.
FAQ
What was Cutera's revenue for Q4 2023?
What was Cutera's full-year 2023 revenue compared to 2022?
What were Cutera's cash and marketable securities as of December 31, 2023?
What was the gross profit for Q4 2023?
What is the 2024 revenue outlook for Cutera?
When is the conference call scheduled to discuss financial results?
